Stock stagnation prompts a 16% pay cut for AstraZeneca CEO Pascal Soriot despite strong sales sheet

Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in its deep portfolio achieving blockbuster sales.

But the British drugmaker did not compensate its CEO accordingly, as Pascal Soriot’s pay package dipped 16% from 17.4 million pounds sterling ($21.9 million) in 2023 to 14.7 million pounds ($18.5 million), according to the company’s annual report.